文献速递肿瘤 PET/CT核素与放射性配体治疗

用于SPECT显像和188Re治疗的99mTc标记FAPI示踪剂的设计与开发

Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy.
PubMed 文献 · J Nucl Med · 2020-03-13

研究开发了99mTc标记的FAP抑制剂示踪剂用于SPECT显像及188Re治疗。先导候选药物99mTc-FAPI-34在体外显示高亲和力(半数抑制浓度6.4-12.7 nM)和显著肿瘤摄取,并在2例转移性卵巢癌和胰腺癌患者中成功显像。所用螯合剂允许用治疗性核素188Re进行标记,计划近期开展。

要点

  • 99mTc-FAPI-34在体外对FAP表达细胞显示高亲和力,半数抑制浓度为6.4-12.7 nM。
  • 99mTc-FAPI-34在生物分布研究中显示显著肿瘤摄取,每克组织摄取注射剂量≤5.4%。
  • 99mTc-FAPI-34在2例转移性卵巢癌和胰腺癌患者中成功用于诊断显像和SPECT。

核心结论

  • 99mTc-FAPI-34是诊断显像的有力示踪剂,尤其在PET显像不可用时。
  • 该化合物所用螯合剂允许用治疗性核素188Re标记,计划近期开展。

研究设计与样本

  • 研究为示踪剂设计与开发,在体外用FAP转染的HT-1080细胞、表达小鼠FAP的HEK细胞和表达CD26的HEK细胞进行结合与竞争实验,并在荷瘤小鼠中进行平面闪烁显像和器官分布研究。
  • 在2例分别为卵巢癌和胰腺癌的患者中进行了首次人体应用。

主要发现

  • 99mTc-FAPI-19对重组FAP表达细胞显示特异性结合且亲和力高,但在HT-1080-FAP异种移植小鼠的平面闪烁显像中观察到肝脏蓄积、胆道排泄且无肿瘤摄取。
  • 将亲水性氨基酸连接至螯合部分后,所得99mTc标记FAPI示踪剂显示优异结合特性(结合率≤45%;内化率>95%)、高亲和力(半数抑制浓度6.4-12.7 nM)及显著肿瘤摄取(每克组织摄取注射剂量≤5.4%)。
  • 先导候选药物99mTc-FAPI-34在2例转移性卵巢癌和胰腺癌患者中用于诊断闪烁显像和SPECT随访(治疗后为90Y-FAPI-46),99mTc-FAPI-34在肿瘤病灶中蓄积,68Ga-FAPI-46 PET/CT显像也显示相同结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most epithelial tumors recruit fibroblasts and other nonmalignant cells and activate them into cancer-associated fibroblasts. This often leads to overexpression of the membrane serine protease fibroblast-activating protein (FAP). It has already been shown that DOTA-bearing FAP inhibitors (FAPIs) generate high-contrast images with PET/CT scans. Since SPECT is a lower-cost and more widely available alternative to PET, 99mTc-labeled FAPIs represent attractive tracers for imaging applications in a larger number of patients. Furthermore, the chemically homologous nuclide 188Re is available from generators, which allows FAP-targeted endoradiotherapy. Methods: For the preparation of 99mTc-tricarbonyl complexes, a chelator was selected whose carboxylic acids can easily be converted into various derivatives in the finished product, enabling a platform strategy based on the original tracer. The obtained 99mTc complexes were investigated in vitro by binding and competition experiments on FAP-transfected HT-1080 (HT-1080-FAP) or on mouse FAP-expressing (HEK-muFAP) and CD26-expressing (HEKCD26) HEK cells and characterized by planar scintigraphy and organ distribution studies in tumor-bearing mice. Furthermore, a first-in-humans application was done on 2 patients with ovarian and pancreatic cancer, respectively. Results:99mTc-FAPI-19 showed specific binding to recombinant FAP-expressing cells with high affinity. Unfortunately, liver accumulation, biliary excretion, and no tumor uptake were observed on planar scintigraphy for a HT-1080-FAP-xenotransplanted mouse. To improve the pharmacokinetic properties, hydrophilic amino acids were attached to the chelator moiety of the compound. The resulting 99mTc-labeled FAPI tracers revealed excellent binding properties (≤45% binding; >95% internalization), high affinity (half-maximal inhibitory concentration, 6.4-12.7 nM), and significant tumor uptake (≤5.4% injected dose per gram of tissue) in biodistribution studies. The lead candidate 99mTc-FAPI-34 was applied for diagnostic scintigraphy and SPECT of patients with metastasized ovarian and pancreatic cancer for follow-up to therapy with 90Y-FAPI-46. 99mTc-FAPI-34 accumulated in the tumor lesions, as also shown on PET/CT imaging using 68Ga-FAPI-46. Conclusion:99mTc-FAPI-34 represents a powerful tracer for diagnostic scintigraphy, especially when PET imaging is not available. Additionally, the chelator used in this compound allows labeling with the therapeutic nuclide 188Re, which is planned for the near future.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lindner T, Altmann A, Krämer S, et al. Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy. J Nucl Med. 2020. PMID: 32169911. doi:10.2967/jnumed.119.239731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。